122 results
8-K
EX-99.1
MRKR
Marker Therapeutics Inc
8 Apr 24
Other Events
7:09am
modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4
8-K
EX-99.2
MRKR
Marker Therapeutics Inc
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
arising directly or indirectly from the use of this presentation. Certain information set forth herein includes estimates, projections and targets … of such estimates, projections or targets or that all assumptions relating to such estimates, projections or targets have been considered or stated
8-K
EX-99.1
MRKR
Marker Therapeutics Inc
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill … tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients
8-K
EX-99.1
MRKR
Marker Therapeutics Inc
11 Dec 23
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
7:35am
-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1 … tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack
8-K
EX-99.1
1ozskg3ncflhsr143e
9 Nov 23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
5:03pm
8-K
EX-99.1
jl9voz
11 Sep 23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
7:10am
8-K
EX-99.1
w32 g9n2ieluv
14 Aug 23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:37pm
8-K
EX-99.1
cxxqmz
7 Aug 23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7:22am
8-K
EX-99.1
ya48ki wdlwzc12
10 Jul 23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
7:09am
8-K
EX-99.1
dn9ed677fud 7hzo84
26 Jun 23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
7:14am
8-K
EX-99.1
ugf61i2z
12 Jun 23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
7:09am
8-K
EX-99.1
uxfl2idkkg1
31 May 23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
6:44am
8-K
EX-99.1
w3kcor09 izbay
8 May 23
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
7:45am
8-K
EX-99.1
f02bv8jzc
1 May 23
MaRKER Announces LeADERSHIP TRANSITION & ProVIdes UPDATE ON OPERATIONAL STRATEGY
7:36am
8-K
EX-99.1
6ph9ek
13 Dec 22
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
7:30am